awmsg logo



abacavir/lamivudine (Kivexa®)


Reference No. 1

Publication date:
25/11/2008


Appraisal information

abacavir/lamivudine (Kivexa®) 600 mg/300 mg film-coated tablet


Company: GlaxoSmithKline
BNF category: Infections
NMG meeting date: 17/09/2008
AWMSG meeting date: 15/10/2008
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2008
Ministerial ratification: 18/11/2008

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Fixed dose abacavir and lamivudine (Kivexa®) is recommended as an option for use within NHS Wales in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV-1) infection in adults and adolescents from 12 years of age. Use should be in accordance with the British HIV Association (BHIVA) guidance. Fixed dose abacavir and lamivudine (Kivexa®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download